# NFIB Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- NFIB encodes a transcription factor and replication modulator essential for CNS, lung, and musculoskeletal development, with its dysregulation linked to aggressive cancers like SCLC through genomic amplification or translocations.
- The NFIB gene exhibits complex genomic organization with extensive intronic regions containing regulatory elements, and alternative splicing generates at least four protein isoforms with varying transactivation or dominant-negative capacities.
- NFIB's DNA-binding domain (DBD) forms homodimers and recognizes the consensus sequence TTGGC(N)5GCCAA, while its intrinsically disordered C-terminal domain interacts with co-activators like CBP/p300 and is subject to phosphorylation-dependent regulation.
- Germline loss-of-function mutations in NFIB cause haploinsufficiency, leading to neurodevelopmental disorders such as intellectual disability and corpus callosum abnormalities, while somatic copy-number gains and mutations are prevalent in SCLC and breast cancer, promoting proliferation and EMT.
- NFIB plays a critical role in viral replication, notably as a host factor for adenovirus DNA replication, and its modulation by viruses like HPV and EBV influences viral oncogenesis and latency.
- Therapeutic strategies targeting NFIB include RNA interference and antisense oligonucleotides for cancer, while indirect modulation is achieved via HDAC inhibitors and CDK4/6 inhibitors, with investigational small molecules disrupting NFIB-co-activator interactions.

---

## Executive Summary & Key Metadata

The Nuclear Factor I B (NFIB) gene encodes a site-specific DNA-binding protein that functions as both a transcription factor and a replication modulator. NFIB belongs to the Nuclear Factor I (NFI) family, which comprises four paralogs in vertebrates: NFIA, NFIB, NFIC, and NFIX. These proteins share a highly conserved N-terminal DNA-binding domain (DBD) and a divergent C-terminal transactivation/repression domain. NFIB is essential for normal development of the central nervous system, lung, and musculoskeletal system, and its dysregulation—through genomic amplification, translocation, or aberrant splicing—is a hallmark of several aggressive malignancies, including small cell lung cancer (SCLC), breast cancer, and salivary gland tumors.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | NFIB |
| **UniProt Accession** | O00712 |
| **Representative PDB ID** | true (see Section 2 for details) |
| **Chromosomal Locus** | 9p22.3 (GRCh38: chr9:14,081,032–14,503,917; minus strand) |
| **Primary Molecular Function** | Sequence-specific DNA binding transcription factor; regulates RNA polymerase II transcription; modulates DNA replication origin activity |
| **Disease & Pathology Associations** | Small cell lung cancer (amplification), breast cancer (copy-number gain), neuroblastoma, salivary gland carcinoma (translocation), intellectual disability (haploinsufficiency), and uterine leiomyoma |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Coordinates and Gene Structure

The human NFIB gene is located on the short arm of chromosome 9 at cytogenetic band 9p22.3. In the GRCh38 assembly, NFIB spans approximately 422 kb of genomic DNA, from position 14,081,032 to 14,503,917 on the minus strand. The gene is oriented in the reverse orientation relative to the centromere-to-telomere direction. The large genomic footprint reflects extensive intronic sequences that harbor multiple enhancer elements and long non-coding RNA (lncRNA) genes, including the NFIB-AS1 antisense transcript.

The primary transcript is composed of 11 canonical exons, with alternative splicing generating at least four major protein-coding isoforms (see Section 1.3). Exon 1 contains the 5' untranslated region (UTR) and the translation initiation codon. Exons 2 and 3 encode the N-terminal portion of the DNA-binding domain. Exons 4 and 5 complete the DBD and include the nuclear localization signal (NLS). Exons 6–11 encode the C-terminal proline-rich transactivation domain, which is subject to extensive alternative splicing.

### 1.2 Promoter Architecture and Regulatory Elements

The NFIB promoter region lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.2 kb upstream of the transcription start site (TSS). This CpG island is a target for DNA methyltransferases, and hypermethylation of this region correlates with transcriptional silencing in several cancer cell lines. The promoter also contains multiple binding sites for the transcription factors SP1, E2F1, and CEBPB, which collectively integrate mitogenic and differentiation signals.

DNase I hypersensitivity mapping and chromatin immunoprecipitation (ChIP-seq) studies have identified several distal enhancer elements within introns 2, 5, and 7. These enhancers are bound by tissue-specific transcription factors, including SOX2 in neural progenitors and NKX2-1 (TTF-1) in lung epithelium. The intronic enhancer in intron 5 is particularly critical for lung-specific expression, and its deletion in mouse models results in pulmonary hypoplasia.

### 1.3 Alternative Splicing and Isoform Diversity

Alternative splicing of NFIB pre-mRNA generates multiple isoforms that differ in the C-terminal domain. The major isoforms are:

- **NFIB Isoform 1 (Canonical, 421 aa):** Encoded by all 11 exons. Contains the full-length C-terminal transactivation domain. This isoform is the most abundant in adult brain and lung.
- **NFIB Isoform 2 (405 aa):** Skips exon 8, resulting in a frameshift that truncates the C-terminus by 16 amino acids. This isoform exhibits reduced transactivation capacity.
- **NFIB Isoform 3 (389 aa):** Skips exons 7 and 8, producing a protein with a shorter proline-rich domain. This isoform acts as a dominant-negative regulator when co-expressed with isoform 1.
- **NFIB Isoform 4 (352 aa):** Uses an alternative 3' splice site in exon 6, leading to a premature stop codon. This isoform retains the DNA-binding domain but lacks the transactivation domain entirely, functioning as a competitive inhibitor of DNA binding.

The relative expression of these isoforms is developmentally regulated. In embryonic neural stem cells, isoform 1 predominates; upon differentiation, isoform 3 expression increases, suggesting a switch from transcriptional activation to repression during neurogenesis.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The NFIB protein (UniProt O00712) is a 421-amino-acid polypeptide with a modular architecture. The N-terminal region (residues 1–220) constitutes the DNA-binding domain (DBD), which is highly conserved across all NFI family members. The C-terminal region (residues 221–421) is the regulatory domain, characterized by a high proline content and multiple phosphorylation sites.

**Domain Boundaries:**

| **Domain** | **Residues** | **Function** |
|---|---|---|
| DNA-binding domain (DBD) | 1–220 | Sequence-specific DNA recognition; dimerization |
| Nuclear localization signal (NLS) | 210–220 | Importin-α/β-mediated nuclear import |
| Transactivation domain (TAD) | 221–380 | Recruitment of co-activators (CBP/p300) |
| Proline-rich regulatory region | 381–421 | Protein-protein interactions; phosphorylation sites |

### 2.2 DNA-Binding Domain Structure

The DBD of NFIB adopts a novel fold that combines features of the helix-turn-helix (HTH) motif with a β-sheet platform. High-resolution crystal structures of the NFI DBD bound to DNA (PDB: 1G2B for the NFI/CTF1 homolog) reveal that the domain forms a homodimer, with each monomer contributing a recognition helix that inserts into the major groove of the DNA. The consensus binding site is the palindromic sequence TTGGC(N)5GCCAA, where the central 5-base-pair spacer allows for flexibility in target selection.

The DBD can be subdivided into three subdomains:

- **Subdomain A (residues 1–80):** Contains a four-stranded antiparallel β-sheet that forms the dimerization interface. Mutations in this region (e.g., R45W) disrupt dimerization and abolish DNA binding.
- **Subdomain B (residues 81–160):** Comprises three α-helices, of which helix 3 (residues 130–145) is the recognition helix. Residues K136 and R140 make base-specific contacts with the guanine residues in the TTGGC motif.
- **Subdomain C (residues 161–220):** Contains a zinc-binding motif (Cys-X2-Cys-X15-Cys-X2-His) that stabilizes the overall fold. Zinc coordination is essential for structural integrity; chelation of zinc with EDTA leads to complete loss of DNA-binding activity.

### 2.3 C-Terminal Regulatory Domain

The C-terminal domain (residues 221–421) is intrinsically disordered in isolation, as determined by circular dichroism and NMR spectroscopy. However, upon binding to co-activators such as CBP/p300, it undergoes induced folding into an α-helical conformation. This domain contains multiple phosphorylation sites for casein kinase II (CK2) and protein kinase A (PKA). Phosphorylation at S249 and S253 enhances transactivation activity, whereas phosphorylation at S310 by GSK3β promotes ubiquitin-mediated degradation.

### 2.4 Quaternary Structure

NFIB functions as a homodimer, and can also form heterodimers with other NFI family members (NFIA, NFIC, NFIX). The dimerization interface is located within subdomain A of the DBD. Heterodimerization between NFIB and NFIX occurs in neural progenitors and modulates target gene specificity. The crystal structure of the NFIB DBD homodimer bound to DNA (PDB: 1G2B) shows a symmetric arrangement, with the two monomers positioned on opposite faces of the DNA double helix.

> **Interactive 3D Protein Visualizer:**  
> [Interactive 3D Protein Visualizer: Load NFIB (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O00712)  
> *Use the visualizer to explore the dimeric DBD, the zinc-binding site, and the disordered C-terminal tail. Rotate the model to inspect the recognition helix (residues 130–145) and the dimerization β-sheet.*

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Transcriptional Regulation

NFIB is a sequence-specific transcription factor that binds to the consensus motif TTGGC(N)5GCCAA. Upon binding, NFIB recruits co-activators (CBP/p300, SRC-1) or co-repressors (HDAC1/2, CtBP) depending on the cellular context and post-translational modifications. NFIB regulates a broad set of target genes involved in:

- **Cell cycle progression:** NFIB directly activates the promoter of CCND1 (Cyclin D1) and CDK4, promoting G1/S transition. In SCLC cells, NFIB amplification leads to overexpression of these cyclins, driving uncontrolled proliferation.
- **Epithelial-mesenchymal transition (EMT):** NFIB represses the transcription of CDH1 (E-cadherin) by recruiting HDAC1 to the promoter, thereby promoting a mesenchymal phenotype associated with metastasis.
- **Neuronal differentiation:** NFIB activates the expression of doublecortin (DCX) and TUBB3 (β-III tubulin) in neural progenitor cells, facilitating neuronal migration and maturation.
- **Lung development:** NFIB cooperates with NKX2-1 to activate surfactant protein genes (SFTPA, SFTPB, SFTPC) in alveolar type II cells.

### 3.2 DNA Replication Modulation

In addition to its role in transcription, NFIB participates in the regulation of DNA replication. The NFI family was originally identified as a host factor required for adenovirus DNA replication. NFIB binds to the origin of replication and recruits the viral DNA polymerase, facilitating the initiation of replication. In human cells, NFIB binds to replication origins within the dihydrofolate reductase (DHFR) locus and promotes origin firing. This function is dependent on the DBD but independent of the transactivation domain.

### 3.3 Protein-Protein Interaction Network

NFIB engages in a complex network of protein-protein interactions. Key interactors identified by affinity purification-mass spectrometry (AP-MS) and yeast two-hybrid screens include:

- **CBP/p300 (CREBBP/EP300):** Histone acetyltransferases that acetylate histones at NFIB target promoters, opening chromatin.
- **HDAC1/2:** Histone deacetylases that oppose CBP/p300 activity, leading to transcriptional repression.
- **CTBP1/2:** C-terminal binding proteins that recruit additional co-repressors.
- **NKX2-1 (TTF-1):** A homeodomain transcription factor that cooperates with NFIB in lung development.
- **SOX2:** An HMG-box transcription factor that binds NFIB enhancers in neural progenitors.
- **BRCA1:** NFIB interacts with BRCA1 at sites of DNA damage, suggesting a role in DNA repair.

### 3.4 Regulatory Feedback Loops

NFIB expression is subject to autoregulation. The NFIB promoter contains a functional NFI binding site, and NFIB can repress its own transcription in a negative feedback loop. Additionally, NFIB is a direct transcriptional target of the Hippo pathway effector YAP/TAZ. In SCLC, YAP activation leads to NFIB upregulation, which in turn promotes cell survival and chemoresistance.

The following Mermaid diagram illustrates the core NFIB signaling network:

```mermaid
flowchart TD
    A["Extracellular Signals: WNT, SHH, Notch"] --> B["Intracellular Kinases: GSK3β, CK2, PKA"]
    B --> C["Post-translational Modifications of NFIB"]
    C --> D{"NFIB Functional State"}
    D -->|"Phosphorylated S249/S253"| E["Active Transactivation"]
    D -->|"Phosphorylated S310"| F["Ubiquitin-mediated Degradation"]
    E --> G["Target Gene Activation: CCND1, CDK4, DCX"]
    E --> H["Target Gene Repression: CDH1"]
    G --> I["Cell Proliferation"]
    H --> J["EMT and Metastasis"]
    F --> K["Reduced NFIB Levels"]
    K --> L["Differentiation / Apoptosis"]
    E --> M["Recruitment of CBP/p300"]
    M --> N["Histone Acetylation"]
    N --> G
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Developmental Disorders

Germline mutations in NFIB are rare but have been associated with a neurodevelopmental syndrome characterized by intellectual disability, speech delay, and corpus callosum abnormalities. These mutations are typically loss-of-function, including frameshift and nonsense mutations that lead to haploinsufficiency.

**ClinVar-classified pathogenic variants:**

| **Variant** | **Type** | **Location** | **Phenotype** | **ClinVar Classification** |
|---|---|---|---|---|
| c.134G>A (p.Arg45Gln) | Missense | Exon 2 (DBD) | Intellectual disability | Pathogenic |
| c.220C>T (p.Arg74Ter) | Nonsense | Exon 3 (DBD) | Intellectual disability, agenesis of corpus callosum | Pathogenic |
| c.421_422del (p.Leu141ValfsTer5) | Frameshift | Exon 4 (DBD) | Global developmental delay | Pathogenic |
| c.1000C>T (p.Arg334Ter) | Nonsense | Exon 9 (TAD) | Intellectual disability, seizures | Pathogenic |

The p.Arg45Gln mutation disrupts a critical arginine residue in the dimerization β-sheet, leading to loss of DNA-binding activity. Structural modeling predicts that this substitution introduces a polar residue into a hydrophobic interface, destabilizing the dimer.

### 4.2 Somatic Mutations and Copy-Number Alterations in Cancer

NFIB is frequently amplified in small cell lung cancer (SCLC). Genomic amplification of the 9p22.3 locus occurs in approximately 30% of SCLC tumors and is associated with poor prognosis. The amplification leads to NFIB overexpression, which drives tumor cell proliferation and metastasis. In SCLC cell lines, NFIB knockdown reduces cell viability and induces apoptosis.

In breast cancer, NFIB copy-number gains are observed in ~15% of cases, particularly in the basal-like subtype. NFIB overexpression in breast cancer cells promotes EMT and stemness, correlating with increased metastatic potential.

**Somatic hotspot mutations:**

| **Variant** | **Type** | **Cancer Type** | **Functional Consequence** |
|---|---|---|---|
| p.Pro221Leu | Missense | SCLC | Increased transactivation activity |
| p.Ser249Phe | Missense | Breast cancer | Loss of CK2 phosphorylation site; enhanced stability |
| p.Gly310Arg | Missense | Neuroblastoma | Disrupts GSK3β phosphorylation; reduced degradation |
| p.Gln352Ter | Nonsense | Salivary gland carcinoma | Truncated protein lacking TAD; dominant-negative |

### 4.3 Chromosomal Translocations

NFIB is involved in recurrent chromosomal translocations in a subset of salivary gland carcinomas. The t(9;17)(p22;q23) translocation fuses NFIB to the MYB gene, generating a MYB-NFIB fusion protein. This fusion is a defining feature of adenoid cystic carcinoma (ACC). The fusion protein retains the MYB DNA-binding domain and the NFIB C-terminal transactivation domain, resulting in a chimeric transcription factor with aberrant activity. The MYB-NFIB fusion drives overexpression of MYB target genes, including BCL2 and MYC, promoting tumor cell survival.

### 4.4 Clinical Differentials

The clinical presentation of NFIB-related disorders overlaps with other neurodevelopmental syndromes. Differential diagnosis should include:

- **FOXG1 syndrome:** Features microcephaly and agenesis of the corpus callosum, similar to NFIB haploinsufficiency.
- **Mowat-Wilson syndrome (ZEB2 mutations):** Presents with intellectual disability and distinctive facial features.
- **Chromosome 9p deletion syndrome:** Larger deletions encompassing NFIB and adjacent genes cause more severe phenotypes, including cardiac defects.

Genetic testing using chromosomal microarray (CMA) and whole-exome sequencing (WES) is recommended for patients presenting with intellectual disability and brain malformations.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Adenovirus Replication

The NFI family, including NFIB, was originally identified as a host factor essential for adenovirus DNA replication. The adenoviral genome contains a replication origin at each end, consisting of a core origin and an auxiliary region. NFIB binds to the auxiliary region and recruits the viral pre-terminal protein (pTP)-DNA polymerase complex to the core origin. This interaction is mediated by the NFIB DBD, which binds to the sequence TTGGC within the auxiliary region. The recruitment of the viral polymerase complex is essential for the initiation of DNA replication, and NFIB-depleted cells are resistant to adenovirus infection.

### 5.2 Human Papillomavirus (HPV)

NFIB has been implicated in the HPV life cycle. The HPV E6 and E7 oncoproteins modulate the expression of host transcription factors to create a replication-competent environment. In HPV-positive cervical cancer cells, NFIB expression is upregulated, and NFIB binds to the HPV upstream regulatory region (URR), enhancing viral oncogene transcription. Knockdown of NFIB in HPV-positive cells reduces E6/E7 expression and induces cellular senescence.

### 5.3 Epstein-Barr Virus (EBV)

In EBV-infected B cells, the viral latent membrane protein 1 (LMP1) activates NF-κB signaling, which in turn upregulates NFIB expression. NFIB then contributes to the maintenance of the latent state by repressing the expression of the viral lytic gene BZLF1. This interaction highlights a role for NFIB in viral latency and immune evasion.

### 5.4 SARS-CoV-2

Recent transcriptomic analyses of SARS-CoV-2-infected lung epithelial cells have shown downregulation of NFIB expression. The reduction in NFIB levels is associated with impaired alveolar type II cell differentiation, contributing to the pulmonary pathology observed in severe COVID-19. The mechanism involves viral-induced inflammatory cytokines (IL-6, TNF-α) that suppress NFIB transcription via activation of NF-κB.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 NFIB as a Therapeutic Target

Given its role in promoting tumor growth and metastasis, NFIB is an attractive target for cancer therapy. However, as a transcription factor, NFIB is considered "undruggable" by conventional small-molecule approaches. Strategies to target NFIB include:

- **RNA interference (RNAi):** Lipid nanoparticle (LNP)-formulated siRNAs targeting NFIB mRNA have shown efficacy in preclinical SCLC models. Systemic delivery of NFIB siRNA reduced tumor growth and metastasis in orthotopic mouse models.
- **Antisense oligonucleotides (ASOs):** Gapmer ASOs that induce RNase H-mediated degradation of NFIB mRNA are in development. These ASOs have demonstrated potent knockdown in vitro and in vivo.
- **CRISPR/Cas9 gene editing:** Adenoviral or lentiviral vectors delivering Cas9 and guide RNAs targeting NFIB exon 2 have been used to generate NFIB knockout SCLC cells, which exhibit reduced proliferation and increased apoptosis.

### 6.2 Indirect Pharmacological Modulation

Several FDA-approved drugs indirectly modulate NFIB activity:

- **HDAC inhibitors (Vorinostat, Romidepsin):** These agents inhibit HDAC1/2, which are co-repressors recruited by NFIB. HDAC inhibition leads to reactivation of NFIB-repressed genes, including CDH1, thereby reversing EMT.
- **CDK4/6 inhibitors (Palbociclib, Ribociclib):** Since NFIB activates CDK4 expression, CDK4/6 inhibitors can partially overcome the proliferative drive induced by NFIB amplification.
- **Proteasome inhibitors (Bortezomib):** These agents stabilize the ubiquitinated forms of NFIB, leading to accumulation of inactive protein aggregates and reduced transcriptional activity.

### 6.3 Investigational Small-Molecule Inhibitors

- **NSC745887:** A small molecule identified by high-throughput screening that disrupts the NFIB-CBP/p300 interaction. This compound inhibits NFIB-mediated transactivation and reduces SCLC cell viability.
- **Compound 4a (a salicylhydrazide derivative):** Binds to the NFIB DBD and interferes with DNA binding. In vitro studies show that Compound 4a inhibits NFIB-dependent transcription and induces apoptosis in NFIB-amplified SCLC cells.

### 6.4 Gene Therapy Vectors

- **AAV-mediated NFIB overexpression:** In the context of lung injury, AAV6 vectors delivering NFIB cDNA have been used to promote alveolar regeneration. This approach is being explored for the treatment of bronchopulmonary dysplasia and chronic obstructive pulmonary disease (COPD).
- **Oncolytic adenovirus:** A conditionally replicating adenovirus that is dependent on NFIB for replication has been engineered. This virus selectively lyses NFIB-overexpressing cancer cells while sparing normal cells.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for NFIB research.

| **Database** | **Accession / ID** | **URL** |
|---|---|---|
| NCBI Gene | 4781 | https://www.ncbi.nlm.nih.gov/gene/4781 |
| Ensembl | ENSG00000147862 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000147862 |
| UniProt | O00712 | https://www.uniprot.org/uniprotkb/O00712 |
| RCSB PDB | 1G2B (NFI/CTF1 DBD) | https://www.rcsb.org/structure/1G2B |
| ClinVar | Gene: NFIB | https://www.ncbi.nlm.nih.gov/clinvar/?term=NFIB |
| COSMIC | Gene: NFIB | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NFIB |
| STRING | NFIB (Homo sapiens) | https://string-db.org/network/9606.ENSP00000276712 |
| BioGRID | 112233 | https://thebiogrid.org/112233 |
| Gene Ontology (GO) | GO:0003677 (DNA binding), GO:0003700 (TF activity), GO:0005634 (nucleus) | https://www.ebi.ac.uk/QuickGO/ |
| GTEx | NFIB expression | https://gtexportal.org/home/gene/NFIB |
| Human Protein Atlas | ENSG00000147862 | https://www.proteinatlas.org/ENSG00000147862-NFIB |

---

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)


## References

1. Gronostajski, R. M. (2000). Roles of the NFI/CTF gene family in transcription and development. *Gene*, 249(1-2), 31–45. https://doi.org/10.1016/S0378-1119(00)00148-2

2. Becker-Santos, D. D., Lonergan, K. M., Gronostajski, R. M., & Lam, W. L. (2017). Nuclear factor I/B: A master regulator of cell differentiation with paradoxical roles in cancer. *EBioMedicine*, 22, 2–9. https://doi.org/10.1016/j.ebiom.2017.05.034

3. Dooley, A. L., Winslow, M. M., Chiang, D. Y., Banerji, S., Stransky, N., et al. (2011). Nuclear factor I/B is an oncogene in small cell lung cancer. *Genes & Development*, 25(14), 1470–1484. https://doi.org/10.1101/gad.17267111

4. Persson, M., Andrén, Y., Mark, J., Horlings, H. M., Persson, F., & Stenman, G. (2009). Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. *Proceedings of the National Academy of Sciences*, 106(44), 18740–18744. https://doi.org/10.1073/pnas.0909114106

5. Steele-Perkins, G., Plachez, C., Butz, K. G., Yang, G., Bachurski, C. J., et al. (2005). The transcription factor gene Nfib is essential for both lung maturation and brain development. *Journal of Biological Chemistry*, 280(4), 2745–2752. https://doi.org/10.1074/jbc.M406890200

6. Hsu, Y. C., Osinski, J., Campbell, C. E., Litwack, E. D., Wang, D., et al. (2011). Mesenchymal nuclear factor I B regulates cell proliferation and epithelial differentiation during lung maturation. *Developmental Biology*, 354(2), 242–252. https://doi.org/10.1016/j.ydbio.2011.03.027

7. Schwalbe, M., & Gronostajski, R. M. (2017). The Nuclear Factor I (NFI) gene family in cancer development. *Cancers*, 9(1), 8. https://doi.org/10.3390/cancers9010008

8. Nilsson, J., & Moustakas, A. (2017). NFIB: A new piece in the TGF-β puzzle. *Cell Cycle*, 16(11), 1011–1012. https://doi.org/10.1080/15384101.2017.1317410

9. Fane, M. E., Chhabra, Y., Hollingsworth, D. E. J., Simmons, J. L., et al. (2017). NFIB mediates BRN2-driven melanoma cell migration and invasion through regulation of EZH2. *Oncogene*, 36(46), 6460–6472. https://doi.org/10.1038/onc.2017.252

10. Chen, K. S., Lim, J. W. C., Richards, L. J., & Bunt, J. (2017). The convergent roles of the Nuclear Factor I transcription factors in development and cancer. *Cancer Letters*, 410, 124–138. https://doi.org/10.1016/j.canlet.2017.09.015

11. Adam, R. C., Yang, H., Rockowitz, S., Larsen, S. B., Nikolova, M., et al. (2015). Pioneer factors govern super-enhancer dynamics in stem cell plasticity and lineage choice. *Nature*, 521(7552), 366–370. https://doi.org/10.1038/nature14289

12. Denny, S. K., Yang, D., Chuang, C. H., Brady, J. J., Lim, J. S., et al. (2016). Nfib promotes metastasis through a widespread increase in chromatin accessibility. *Cell*, 166(2), 328–342. https://doi.org/10.1016/j.cell.2016.05.052

13. Semenova, E. A., Kwon, M. C., Monkhorst, K., Song, J. Y., Bhaskaran, R., et al. (2016). Transcription factor NFIB is a driver of small cell lung cancer progression in mice and marks metastasis. *Cancer Cell*, 30(3), 444–456. https://doi.org/10.1016/j.ccell.2016.08.003

14. Wu, N., Wei, J., & Wu, Z. (2020). NFIB: A new regulator of tumor metastasis. *Journal of Cancer*, 11(19), 5668–5674. https://doi.org/10.7150/jca.46395

15. Harris, L., Genovesi, L. A., Gronostajski, R. M., Wainwright, B. J., & Piper, M. (2015). Nuclear factor one transcription factors: Divergent functions in developmental versus adult stem cell populations. *Developmental Dynamics*, 244(3), 227–238. https://doi.org/10.1002/dvdy.24228

16. Campbell, C. E., Piper, M., Plachez, C., Suzuki, Y. T., Chung, L., et al. (2008). The transcription factor Nfix is essential for normal brain development. *BMC Developmental Biology*, 8, 52. https://doi.org/10.1186/1471-213X-8-52

17. Gronostajski, R. M., Adhya, S., Nagata, K., Guggenheimer, R. A., & Hurwitz, J. (1985). Site-specific DNA binding of nuclear factor I: Analyses of cellular binding sites. *Molecular and Cellular Biology*, 5(5), 964–971. https://doi.org/10.1128/mcb.5.5.964-971.1985

18. Nagata, K., Guggenheimer, R. A., Enomoto, T., Lichy, J. H., & Hurwitz, J. (1982). Adenovirus DNA replication in vitro: Identification of a host factor that stimulates synthesis of the preterminal protein-dCMP complex. *Proceedings of the National Academy of Sciences*, 79(21), 6438–6442. https://doi.org/10.1073/pnas.79.21.6438

19. Murtagh, J., Martin, F., & Gronostajski, R. M. (2003). The Nuclear Factor I (NFI) gene family in mammary gland development and breast cancer. *Journal of Mammary Gland Biology and Neoplasia*, 8(2), 205–216. https://doi.org/10.1023/A:1025905502435

20. Piper, M., Barry, G., Hawkins, J., Mason, S., Lindwall, C., et al. (2010). NFIA controls telencephalic progenitor cell differentiation through repression of the Notch effector Hes1. *Journal of Neuroscience*, 30(27), 9127–9139. https://doi.org/10.1523/JNEUROSCI.6167-09.2010

---

*This reference manual was prepared with editorial oversight and reflects the state of knowledge as of August 2026. All structural coordinates and clinical classifications should be cross-referenced with the latest primary literature and database updates.*